| FMCDX | VEMPX | FMCDX / VEMPX | |
| Total Expense Ratio | 0.93 | 0.04 | 2,325% |
| Annual Report Gross Expense Ratio | 0.93 | 0.04 | 2,325% |
| Fund Existence | 29 years | 15 years | - |
| Gain YTD | 4.558 | 5.786 | 79% |
| Front Load | 6% | N/A | - |
| Min. Initial Investment | 0 | 100000000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.16B | 83.9B | 3% |
| Annual Yield % from dividends | 0.32 | 1.10 | 29% |
| Returns for 1 year | -1.20 | 2.67 | -45% |
| Returns for 3 years | 20.08 | 45.41 | 44% |
| Returns for 5 years | 19.87 | 36.40 | 55% |
| Returns for 10 years | 40.95 | 140.37 | 29% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| WAAEX | 37.49 | 0.26 | +0.70% |
| Wasatch Small Cap Growth Investor | |||
| DTCCX | 15.90 | 0.06 | +0.38% |
| BNY Mellon Sust US Equity C | |||
| MSVEX | 6.28 | N/A | N/A |
| Morgan Stanley Vitality Portfolio A | |||
| VSFSX | 24.70 | -0.05 | -0.20% |
| Federated Hermes Clover Small Value R6 | |||
| JAGLX | 81.19 | -0.17 | -0.21% |
| Janus Henderson Global Life Sciences T | |||